New York, June 13 (Ians) An experimental vaccine has shown promise in delaying the return of deadly brain tumour and also extending the average survival rate from 15 to 26 months, media reports said.
The vaccine, SurVaxM developed by US biotech company MimiVax, targets a protein found in tumours called survivin, CNBC reported.
When injected into the patient, the jab stimulates the production of T-cells — body’s immune system — which then attack survivin, vital to survival of glioblastomas. The attack destroys the protein, reducing the size of tumours or preventing its growth.
Glioblastoma is one of the most fatal and treatment-resistant cancers, which can result in death in six months or less, if left untreated.
It makes up nearly half of all malignant brain tumours and has a five-year survival rate of 6.8 per cent.
Traditional treatment of glioblastomas typically involves surgery, chemotherapy and radiation. However, unless every cancer cell is eliminated, the tumour often comes back.
The vaccine, SurVaxM developed by US biotech company MimiVax, targets a protein found in tumours called survivin, CNBC reported.
When injected into the patient, the jab stimulates the production of T-cells — body’s immune system — which then attack survivin, vital to survival of glioblastomas. The attack destroys the protein, reducing the size of tumours or preventing its growth.
Glioblastoma is one of the most fatal and treatment-resistant cancers, which can result in death in six months or less, if left untreated.
It makes up nearly half of all malignant brain tumours and has a five-year survival rate of 6.8 per cent.
Traditional treatment of glioblastomas typically involves surgery, chemotherapy and radiation. However, unless every cancer cell is eliminated, the tumour often comes back.
- 6/13/2023
- by Agency News Desk
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.